CA2912743A1 - Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy - Google Patents

Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Info

Publication number
CA2912743A1
CA2912743A1 CA2912743A CA2912743A CA2912743A1 CA 2912743 A1 CA2912743 A1 CA 2912743A1 CA 2912743 A CA2912743 A CA 2912743A CA 2912743 A CA2912743 A CA 2912743A CA 2912743 A1 CA2912743 A1 CA 2912743A1
Authority
CA
Canada
Prior art keywords
chloro
fluoro
day
phenyl
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2912743A
Other languages
English (en)
French (fr)
Inventor
Brian Higgins
Gwen NICHOLS
Kathryn E. Packman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2912743A1 publication Critical patent/CA2912743A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CA2912743A 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy Abandoned CA2912743A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836899P 2013-06-19 2013-06-19
US61/836,899 2013-06-19
PCT/EP2014/062496 WO2014202497A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Publications (1)

Publication Number Publication Date
CA2912743A1 true CA2912743A1 (en) 2014-12-24

Family

ID=50976625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912743A Abandoned CA2912743A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Country Status (12)

Country Link
US (1) US20160129034A1 (https=)
EP (1) EP3010508B1 (https=)
JP (1) JP6549107B2 (https=)
KR (1) KR20160009677A (https=)
CN (1) CN105263499B (https=)
BR (1) BR112015030734A2 (https=)
CA (1) CA2912743A1 (https=)
ES (1) ES2747073T3 (https=)
MX (1) MX2015017124A (https=)
PL (1) PL3010508T3 (https=)
RU (1) RU2015152175A (https=)
WO (1) WO2014202497A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
CN113698435B (zh) * 2021-08-25 2023-09-29 中国人民解放军空军军医大学 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5385125B2 (ja) * 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CN105147713A (zh) * 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
MX2015017124A (es) 2016-03-07
CN105263499B (zh) 2019-11-15
CN105263499A (zh) 2016-01-20
PL3010508T3 (pl) 2019-12-31
RU2015152175A (ru) 2017-07-24
JP2016521760A (ja) 2016-07-25
HK1213475A1 (zh) 2016-07-08
EP3010508A1 (en) 2016-04-27
KR20160009677A (ko) 2016-01-26
EP3010508B1 (en) 2019-07-24
US20160129034A1 (en) 2016-05-12
JP6549107B2 (ja) 2019-07-24
RU2015152175A3 (https=) 2018-04-02
ES2747073T3 (es) 2020-03-10
BR112015030734A2 (pt) 2017-07-25
WO2014202497A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP5046922B2 (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
JP2012515184A (ja) 大腸がんの治療方法
EP2817011B1 (en) Treatment of cancer
WO2022218958A1 (en) Combination comprising everolimus and amcenestrant
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2005525409A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
JP2014504636A (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
EP3010508B1 (en) Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
ES2644237T3 (es) Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
EP3010513B1 (en) Combination of ro5503781 and capecitabine for cancer therapy
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
HK1213475B (zh) 用於癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
WO2025226653A1 (en) Wee1 inhibitor combination therapy dosing regimen
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
HK1204956B (en) Treatment of cancer
JP2001261573A (ja) 腫瘍転移抑制剤
KR20110104932A (ko) Ａｖｅ８０６２ 및 도세탁셀이 조합된 항종양 조합물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190618